Ten-year survival of patients with hepatocellular carcinoma after hepatectomy

Hepato-Gastroenterology

Volumn 54, Issue 73, 2007, Pages 163-166

  Hashimoto, Koji ^a,b   Ikeda, Yasuharu ^a   Korenaga, Daisuke ^a   Tanoue, Kazuo ^a   Hamatake, Motoharu ^a   Kawasaki, Katsumi ^a   Yamaoka, Terutoshi ^a   Iwatani, Yasue ^a   Takenaka, Kenji ^a  

^a Fukuoka City Hospital   (Japan)

^b ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

Author keywords

10 year survival; Hepatectomy; Hepatocellular carcinoma

Indexed keywords

ALBUMIN; BILIRUBIN;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTE COUNT;

AGED; ALBUMINS; BILIRUBIN; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NUTRITIONAL STATUS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SERUM ALBUMIN;

EID: 34047095770     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Takenaka K, Kawahara N, Yamamoto K, et al: Results of 280 liver resections for hepatocellular carcinoma. Arch Surg 1996; 131:71-76.
2. Poon RT, Fan ST, Lo CM, et al: Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999; 229:216-222.
3. The Liver Cancer Study Group of Japan: Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 101:796-802.
4. Ikeda Y, Shimada M, Hasegawa H, et al: Prognosis of hepatocellular carcinoma with diabetes mellitus after hepatic resection. Hepatology 1998; 27:1567-1571.
5. Hashimoto K, Ikeda Y, Korenaga D, et al: The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma Cancer 2005; 103:1856-1864.
6. Kanematsu T, Takenaka K, Matsumata T, et al: Limited hepatic resection effective for selected cirrhotic patients with primary liver cancer. Ann Surg 1984; 199:51-56.
7. Shirabe K, Shimada M, Kajiyama K, et al: Clinicopathologic features of patients with hepatocellular carcinoma surviving >10 years after hepatic resection. Cancer 1998; 83:2312-2316.
8. Nishiguchi S, Kuroki T, Nakatani S, et al: Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346:1051-1055.
9. Ikeda K, Arase Y, Saitoh S, et al: Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32:228-232.
10. Kubo S, Nishiguchi S, Hirohashi K, et al: Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134:963-967.
11. Kimura F, Miyazaki M, Suwa T, et al: Reduction of hepatic acute phase response after partial hepatectomy in elderly patients. Res Exp Med 1996; 196:281-290.
12. Alberino F, Gatta A, Amodio P, et al: Nutrition and survival in patients with liver cirrhosis. Nutrition 2001; 17:445-450.
13. Muto Y, Sato S, Watanabe A, et al: Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol 2005; 3:705-713.
14. The San-in Group of Liver Surgery: Long-term oral administration of branched chain amino acids after curative resection of hepatocellular carcinoma: a prospective randomized trial. Br J Surg 1997; 84:1525-1531.